Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BIBR 1048 MS capsules +/- pantoprazole
NCT02170805Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2001
- Primary completion
- Jun 2001
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dabigatran etexilate oral solution in thromboembolism (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to infinity at 48 hours and Area under the concentration-time curve from 0 to last quantifiable concentration at 48 hours. Started Apr 2001; status: completed.
02
Drugs
dabigatran etexilate oral solution
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02170805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170805.